Probleme bei der Anwendung von Plasmafraktionen

H. Bergmann; B. Blauhut

doi:10.1055/s-0038-1656570

Hämostaseologie, Table of Contents

Hamostaseologie 1982; 02(03): 83-90
DOI: 10.1055/s-0038-1656570

Originalarbeiten

Schattauer GmbH

Probleme bei der Anwendung von Plasmafraktionen

H. Bergmann

¹Aus dem Institut für Anästhesiologie des A. ö. Krankenhauses der Stadt Linz, dem Blutspendedienst vom Roten Kreuz für Oberösterreich und der Außenstelle Linz des Ludwig-Boltzmann-Institutes für experimentelle Anästhesiologie und Intensivmedizinische Forschung (Vorstand/Leiter: Prof. Prim. Dr. H. Bergmann)

,

B. Blauhut

¹Aus dem Institut für Anästhesiologie des A. ö. Krankenhauses der Stadt Linz, dem Blutspendedienst vom Roten Kreuz für Oberösterreich und der Außenstelle Linz des Ludwig-Boltzmann-Institutes für experimentelle Anästhesiologie und Intensivmedizinische Forschung (Vorstand/Leiter: Prof. Prim. Dr. H. Bergmann)

› Author Affiliations

Abstract

Full Text

References

LITERATUR
1 Allain J. T., Verroust F., Soulier J. P. In vitro and in vivo characterization of factor-VIII preparations. Vox Sang. 1980; 38: 68.
2 Alter H. J., Barker L. F., Fiedler H., Frey-Wettstein M., Gitnik G. L., Green- walt T. J., Prince A. M., Reesink H. W., Reinicke V., Seeff L. B., Wright E. C., Zuckerman A. J. International Forum: How fre quent is posttransfusion hepatitis after the introduction of 3rd generation donor screening for hepatitis B? What is its'probable nature?. Vox Sang 1977; 32: 346.
3 Alving B. M., Hojima Y., Pisano J. J., Mason B. L., Buckingham jr. R. E., Mo-zen M. M., Finlayson J. S. Hypotension associated with prekallikrein activator (Hageman-Fac-tor fragments) in plasma protein fraction. New Engl. J. Med. 1978; 299: 66.
4 Bergmann H. Plastikmaterial und Glas in der Blutkonservierung. Münchn. Med. Wschr. 1972; 114: 2209.
5 Bland J. H. L., Laver M. B., Lowenstein E. Hypotension due to 5 per cent plasma protein fraction. New Engl. J. Med. 1972; 286: 109.
6 Blauhut B., Bergmann H., Scheid I., Vinazzer H. Erfahrungen mit der Dauersubstitution von Haemophilen in Oberösterreich. Forschg. Erg. Transf. Med. Immun-haematol. 1980; 6: 63.
7 Bütler R. Epidemiologische Aspekte der Hepatitis bei Hämophilen. Forsch. Erg. Transf. Med. Immunhaematol. 1977; 4: 63.
8 Chandra S., Brummelhuis H. G. J. Prothrombin complex concentrates for clinical use. Vox Sang. 1981; 41: 257.
9 Combridge B. S., Wesley E. D. Plasma protein fraction: The disappearance of kinin from the solution on storage. Transfusion 1979; 19: 599.
10 Frey R., Hutschenreuter K., Ahne-feld F. W., Steinbereithner K. Vorsichtsmaßnahmen bei der Anwendung kolloidaler Volumenersatzmittel. Anaesthesist 1975; 24: 378.
11 Garfield M. D., Ershler W. B., Maki D. G. Malaria transmission by platelet concentrate transfusion. J. Am. Med. Ass. 1978; 240: 2285.
12 Haas R. Epidemiologie und Bluttransfusion aus virologischer Sicht. Forsch. Erg. Transf. Med. Immunhaemat. 1975; 2 II 491.
13 Hardy P. H. The spirochetes. In Davis B. D. (ed.) Microbiology 2nd ed. Harper and Row; Hagerstown: 1973
14 Harrison G. A., Robinson M., Sta-cey R. V. Hypotensive effects of stable plasma protein solution (S. P.P.S.). A preliminary communication. Med. J. Aust. 1971; 2: 1040.
15 Hoofnagle J. H., Barker L. F., Thiel J., Gerety R. J. Hepatitis B virus and hepatitis B surface antigen in human albumin products. Transfusion 1976; 16: 141.
16 Hoofnagle J. H., Gerety R. J., Thiel J., Barker L. F. The prevalence of hepatitis B surface antigen in commercially prepared plasma products. J. Lab. clin. Med. 1976; 88: 102.
17 Hoofnagle J. H., Seeff L. B., Buskell Bales Z., Zimmermann H. J. Veterans Administration Hepatitis Cooperative Study Group: Type B hepatitis after transfusion with blood containing antibody to hepatitis B core antigen. New Engl. J. Med. 1978; 298: 1379.
18 Hossli G. Probleme der Massivtransfusion. »Anaesthesia 74«, Dresden 1974; 18 (21) 11..
19 Ishizaka K., Ishizaka T., Hornbrook M. M. Physicochemical properties of reaginic anti-body. IV. Presence of a unique immunoglobulin as carrier of reaginic activity. J. Immunol. 1966; 97: 75.
20 Izaka K., Tsutsui E., Mima Y., Hasega-wa E. A bradykinin-like substance in heat treated human plasma protein solution. Transfusion 1974; 14: 242.
21 Jaeger R. J., Rubin R. J. Plasticizers from plastic devices: extraction. metabolism and accumulation by biological systems. Science 1970; 170: 460.
22 Johansson S. G. O. Raised levels of a new immunoglobulin (IgNd) in asthma. Lancet 1967; 11: 51.
23 Kacaki J., Wolters G., Kuijpers L., Stulemeyer S. Results of a multicentre clinical trial of the solidphase enzyme immunoassay for hepatitis B surface antigen. Vox Sang. 1978; 35: 65.
24 Katchaki J. N. R., Brouwer T., Siem H. Anti-HBc and blood infectivity. New Engl. J. Med. 1978; 298: 1421.
25 Kernoff P. B. A., Bowell P. J. Gm types and antibodies in multi-transfused haemophiliacs. Br. J. Haemat. 1973; 24: 443.
26 Kevy S. V. What is the toxicological importance of the liberation of phthalates from plastic containers into blood. its components and derivatives? Vox Sang. 1978; 34: 248.
27 Knierim F., Rubinstein P. The detection of Chagas disease. A rapid haemagglutina-tion test for special use in blood banks and epidemiological studies. Vox Sang. 1970; 15: 280.
28 Kotitschke R., Stephan W. Antigen-to-activity ratio of factors II and IX in PPSB concentrates. Haemostasis 1981 10 Suppl. 1
29 Kuwahara S. S. Prekallikrein activator (Hageman factor fragment) in human plasma fractions. Transfusion 1980; 20: 433.
30 Kuwahara S. S., Calera F., Terry E. S. Distribution of polybrominated biphenyls (PBB) among fractions derived from contaminated human plasma. Transfusion 1980; 20: 229.
31 Lindner A., Charra B., Sherrard D. J., Scribner B. H. Accelerated atherosclerosis in prolonged maintenance hemodialysis. New Engl. J. Med. 1974; 290: 697.
32 Liotta I. What is the toxicological importance of the liberation of phthalates from plastic containers into blood. its components and derivatives? Vox Sang. 1978; 34: 249.
33 Maider M. J., Shulman N. R. Major surgery in classic hemophilia using Fraction I. Am. J. Med. 1966; 41: 56.
34 Marley P. B., Gilbo C. M. Temperature sensitivity within the pasteurization temperature range of prekallikrein activator in stable plasma protein solution (SPPS). Transfusion 1981; 21: 320.
35 McMillan C. W., Diamond L. K., Surgenor D. M. A treatment of classic hemophilia. New Engl. J. Med. 1961; 265: 224.
36 Meslet B. J. Y. Anémie hémolytique secondaire au traitement substitutif chez les hémophiles A. Thèse Paris 1975
37 Nair P. P. What is the toxicological importance of the liberation of phthalates from plastic containers into blood. its com-ponents and derivatives? Vox Sang. 1978; 34: 251.
38 Newcombe T. F., Walston M. E. Elective surgery in hemophilia. II. Hematologic control. J. Am. Med. Ass. 1963; 185: 628.
39 Ng P. K., Fournel M. A., Lundblad J. L. Plasma protein fraction. Product improvement studies. Transfusion 1981; 21: 682.
40 Ohlmeier H., Dahmen E., Hoppe I. Hepatitisrisiko von humanen Gerinnungspräparaten aus gepoolten Plasmen. Ergebnisse einer Prospektivstudie. Dtsch. med. Wschr. 1978; 205: 1700.
41 Ohyama T. Effects of phthalate esters on the respiration of rat liver mitochondria. J. Biochem. 1976; 79: 153.
42 Orringer E. P., Koury M. J., Blatt P. M., Roberts H. R. Hemolysis caused by factor VIII concentrates. Arch. intern. Med. 1976; 136: 1018.
43 Papaevangelou G. J. Post-transfusion hepatitis: European perspective and prophylaxis. Bibl. Haemat. 1980; 46: 15.
44 Peck C. C., Zuck T. F. What is the toxicological importance of the liberation of phthalates from plastic containers into blood. its components and derivatives? Vox Sang. 1978; 34: 252.
45 Prager D., Djerassi I., Eyster M. E., Gill F. M., Kajani N. K., Lewis J. H., Lusch C., Rice S., Shapiro S. S. Pennsylvania state-wide hemophilia program: Summary of immediate reactions with the use of factor VIII and factor IX concentrate. Blood 1979; 53: 1012.
46 Preuner R. Allergische. blutgruppenunabhängige Transfusionsstörungen. Bibl. Haemat. 1956; 5: 8.
47 Prince A. M. Use of hepatitis B immune globulin: Reassessment needed. New Engl. J. Med. 299: 198 1978;
48 Pruggmayer D., Stephan W. Gas chromatographic trace analysis of ß-propiolacto-ne in sterilized serum proteins. Vox. Sang. 1976; 31: 191.
49 Rosati L. A., Barnes B., Oberman H. A., Premier J. A. Hemolytic anemia due to anti-A and anti-B in concentrated antihemophilic factor preparations. Arch. intern. Med. 1970; 130: 139.
50 Rubin R. J., Schiffer C. A. Fate in humans of the plasticizer. di-2-ethylhexyl phthalate arising from transfusion of platelets stored in vinyl plastic bags. Transfusion 1976; 16: 330.
51 Seeff L. B., Hoofnagle J. Acute and chronic liver disease in hemophilia. Proceedings of a conference, Bethesda, March 1976. DHEW-Publ.; (NIH): 77-1089 55.
52 Seeler R. A. Hemolysis due to anti-A and anti-B in factor VIII preparations. Arch, intern. Med. 132: 101 1972;
53 Seeler R. A., Telischi M., Langehen-nig P. L., Ashenhurst J. B. Comparison of anti-A and anti-B titers in factor VIII and IX concentrates. J. Pediat. 1976; 89: 87.
54 Sobeslavsky O. Prevalence of markers of hepatitis B virus infection in various countries: A WHO collaborative study. Bull. WHO 1980; 58: 621.
55 Stampfli K. Posttransfusionelle Hepatiti-den mit letalem Verlauf. Schweiz. med. Wschr. 1967; 97: 1487.
56 Stephan W., Kotitschke R. Prothrombin-komplex-Konzentrat aus kaltsterilisiertem Plasma. Forsch. Erg. Trans. Med. Immun-haematol. 1977; 4: 72.
57 Stephan W., Kotitschke R., Prince A. M., Brotman B. Long term tolerance and recovery of ß-propiolactone/ultraviolet treated PPSB in shimpanzees. Thrombos. Haemat. 1981; 46: 511.
58 Tabor E., Aronson D. L., Gerety R. J. Removal of hepatitis B virus infectivity from factor IX complex by hepatitis B immune globulin. Lancet 1980; 2: 68.
59 Tamagnini G. P., Dormandy K. M., Ellis D., Maycock d'A W. Factor VIII concentrate in haemophilia. Lancet 1975; 2: 188.
60 Trepo C., Hantz O., Jacquier M. F., Nemoz G., Cappel R., Trepo D. Different fates of hepatitis B virus markers during plasma fractionation. A clue to the infectivity of blood derivatives. Vox Sang. 1978; 35: 143.
61 Valeri C. R., Contreras T. J., Feingold H., Sheibley R. H., Jaeger R. I. Accumulation of di-2-ethylhexyl phthalate (DEHP) in whole blood. platelet concentrates and platelet-poor plasma. I. Effect of DEHP on platelet survival and function. Envir. Hlth. Perspect. Exp. Issue 1973; 3: 103.
62 Weil M. H., Shubin H. The »VIP« approach to the bedside management of shock. In Weil M. H. H. Shubin: Critical Care Medicine, Current Principles and Practice pp Harper and Row, Ha-gerstown, MD.; New York, San Francisco, London: 1976: 90-98
63 Wickerhauser M., Mercer J. E., Eckenrode J. W. Development of large-scale fractionation methods. VI. An improved method for preparation of antihemophilic factor. Vox Sang. 1978; 35: 18.
64 Wyke R. J., Thornton A., Portmann B., Zuckerman A. J., Tsiquaye K. N., White Y., Das P. K., Williams R. Transmission of non-A non-B hepatitis to chimpanzees by factor-IX concentrates after fatal complications in patients with chronic liver disease. Lancet 1979; 1: 520.